Document is current
Any future updates will be listed below
-
Authors
Senkevich, Konstantin https://orcid.org/0000-0003-3407-5716
Parlar, Sitki Cem
Chantereault, Cloe
Yu, Eric https://orcid.org/0000-0003-3525-4564
Ahmad, Jamil
Ruskey, Jennifer A.
Asayesh, Farnaz
Spiegelman, Dan
Waters, Cheryl
Monchi, Oury https://orcid.org/0000-0003-2148-5409
Dauvilliers, Yves
Dupré, Nicolas
Miliukhina, Irina
Timofeeva, Alla
Emelyanov, Anton
Pchelina, Sofya
Greenbaum, Lior
Hassin-Baer, Sharon
Alcalay, Roy N.
Gan-Or, Ziv https://orcid.org/0000-0003-0332-234X
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research
Parkinson's Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (UL1 TR000040)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (K02NS080915)
Brookdale Foundation
- License Information
-
More Information
Article History
Received: 29 May 2024
Accepted: 2 October 2024
First Online: 25 October 2024
Competing interests
: Z.G.O. received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial, UCB, Capsida, Vanqua bio, Congruence Therapeutics, Takeda, Jazz Pharmaceuticals, Guidepoint, Lighthouse and Deerfield.
